In this issue of JAMA Oncology, Baumann et al1 present a large single-institution retrospective analysis of proton- vs photon-based radiotherapy specifically for patients receiving concurrent chemotherapy for 11 types of locally advanced cancers. Patients undergoing proton therapy overall had significantly fewer grade 3 toxic effects requiring hospitalization at 90 days, as well as fewer grade 2 toxic effects at 90 days and a smaller decline in performance status during treatment.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Park HS, Yu JB. Proton-Based Chemoradiotherapy—What Level of Evidence Is Necessary to Justify Its Widespread Use? JAMA Oncol. 2020;6(2):246–247. doi:10.1001/jamaoncol.2019.4875
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: